Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27976000 | 0.88 | DYRK1A (0.46) | DYRK1APDGFRBPDGFRAMEN1NPC1 | |
| SCHEMBL27976001 | 0.88 | DYRK1A (0.46) | DYRK1APDGFRBPDGFRAMEN1NPC1 | |
| SCHEMBL27976005 | 0.85 | DYRK1A (0.47) | DYRK1APDGFRBPDGFRAMEN1NPC1 | |
| SCHEMBL24985287 | 0.81 | KDM4E (0.60) | MEN1KMT2ATDP1 | |
| SCHEMBL23195545 | 0.81 | MEN1 (0.45) | MEN1LMNAKMT2A | |
| SCHEMBL24985286 | 0.81 | PDE4A (0.43) | MEN1NPC1RAB9AKMT2ATDP1 | |
| SCHEMBL24345422 | 0.81 | HRH1 (0.44) | — | |
| SCHEMBL26525609 | 0.81 | POLB (0.45) | MEN1NPC1LMNARAB9AKMT2A | |
| SCHEMBL20675592 | 0.81 | IDO1 (0.53) | DYRK1AMEN1NPC1LMNARAB9A | |
| SCHEMBL27976334 | 0.81 | MEN1 (0.44) | DYRK1AMEN1NPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503440-B2 | Nitroxoline derivative, preparation method therefor, and use thereof | Jiangsu Yahong Meditech Co. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230295094-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295094-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295094-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| EP-4194441-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| EP-4194441-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| CN-115867540-A | Nitroxoline derivatives, preparation method and application thereof | 江苏亚虹医药科技股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC (US) | 2022-07-14 | — | — | US | disclosed |
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-04-21 | — | — | US | disclosed |
| WO-2022028321-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2022-02-10 | — | — | WO | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10793561-B2 | 1,8-naphthyridinone compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-07-23 | — | — | US | disclosed |
| US-20190023702-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | DYRK1A 1898/4885PDGFRB 475/4885PDGFRA 490/4885 |
| US-12503440-B2 | Nitroxoline derivative, preparation method therefor, and use thereof | NOS1, NQO1, NOS2 | DYRK1A 4182/4885PDGFRB 4153/4885PDGFRA 4457/4885 |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | DYRK1A 4748/4885PDGFRB 2964/4885PDGFRA 3522/4885 |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | DYRK1A 3065/4885PDGFRB 527/4885PDGFRA 656/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | DYRK1A 3065/4885PDGFRB 527/4885PDGFRA 656/4885 |
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | DYRK1A 3065/4885PDGFRB 527/4885PDGFRA 656/4885 |
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | DYRK1A 4859/4885PDGFRB 3330/4885PDGFRA 3699/4885 |
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | DYRK1A 3065/4885PDGFRB 527/4885PDGFRA 656/4885 |
| US-10793561-B2 | 1,8-naphthyridinone compounds and uses thereof | NME1, ADORA2A, GPR68 | DYRK1A 1898/4885PDGFRB 475/4885PDGFRA 490/4885 |
| US-20190023702-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | DYRK1A 1898/4885PDGFRB 475/4885PDGFRA 490/4885 |
| US-20230295094-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | NOS1, NQO1, NOS2 | DYRK1A 4182/4885PDGFRB 4153/4885PDGFRA 4457/4885 |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ACE, ZC3HAV1, SARS1 | DYRK1A 4685/4885PDGFRB 2968/4885PDGFRA 3430/4885 |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | DYRK1A 4752/4885PDGFRB 3009/4885PDGFRA 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.